Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Authors
Keywords
GCG, GIP, GLP-1, metabolic disease, pharmacodynamics, receptor occupancy, safety, triple GLP-1/GIP/GCG receptor agonist, type 2 diabetes
Journal
Cell Metabolism
Volume 34, Issue 1, Pages 59-74.e10
Publisher
Elsevier BV
Online
2021-12-20
DOI
10.1016/j.cmet.2021.12.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
- (2021) Qian Zhang et al. Cell Metabolism
- Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor by Positron Emission Tomography
- (2021) Olof Eriksson et al. DIABETES
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis
- (2020) Rachel J. Perry et al. NATURE
- Current and new pharmacotherapy options for non-alcoholic steatohepatitis
- (2020) Yoshio Sumida et al. EXPERT OPINION ON PHARMACOTHERAPY
- The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists
- (2020) Shweta Urva et al. DIABETES OBESITY & METABOLISM
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Automated GMP-Compliant Production of [68Ga]Ga-DO3A-Tuna-2 for PET Microdosing Studies of the Glucagon Receptor in Humans
- (2020) Michael Wagner et al. Pharmaceuticals
- Dose‐dependent efficacy of the glucose‐dependent insulinotropic polypeptide ( GIP) receptor antagonist GIP (3‐30) NH 2 on GIP actions in humans
- (2020) Lærke Smidt Gasbjerg et al. DIABETES OBESITY & METABOLISM
- Amino acids are sensitive glucagon receptor‐specific biomarkers for glucagon‐like peptide‐1 receptor/glucagon receptor dual agonists
- (2020) Wenyu Li et al. DIABETES OBESITY & METABOLISM
- Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
- (2020) Olof Eriksson et al. Scientific Reports
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- First-in-class positron emission tomography tracer for the glucagon receptor
- (2019) Irina Velikyan et al. EJNMMI Research
- Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes
- (2019) Natasha Chidekel Bergmann et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- Glucagon Regulation of Energy Expenditure
- (2019) Maximilian Kleinert et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Assessment of glucagon receptor occupancy by Positron Emission Tomography in non-human primates
- (2019) Olof Eriksson et al. Scientific Reports
- Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes
- (2019) Valerie D Heuvelman et al. CARDIOVASCULAR RESEARCH
- MEDI0382, a GLP-1-glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomised, phase 1 study
- (2018) Philip D. Ambery et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates
- (2018) Ralf Elvert et al. DIABETES OBESITY & METABOLISM
- Hemodynamic Effects of Glucagon: A Literature Review
- (2018) Kasper Meidahl Petersen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations
- (2018) Andreas Evers et al. JOURNAL OF MEDICINAL CHEMISTRY
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Pharmacotherapy of type 2 diabetes: An update
- (2018) Jagriti Upadhyay et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Animal models of obesity and diabetes mellitus
- (2018) Maximilian Kleinert et al. Nature Reviews Endocrinology
- Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
- (2018) Kirstine S Tølbøl et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Chemical Strategies for Half-Life Extension of Biopharmaceuticals: Lipidation and Its Alternatives
- (2018) Esben M. Bech et al. ACS Medicinal Chemistry Letters
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Peptide Optimization at the Drug Discovery-Development Interface: Tailoring of Physicochemical Properties Toward Specific Formulation Requirements
- (2018) Andreas Evers et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
- (2018) Christoffer Clemmensen et al. Nature Reviews Endocrinology
- Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
- (2018) Piotr A. Mroz et al. Molecular Metabolism
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
- (2018) Marta Seghieri et al. Frontiers in Endocrinology
- Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia
- (2017) Mikkel B Christensen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
- (2017) Andreas Evers et al. JOURNAL OF MEDICINAL CHEMISTRY
- The New Biology and Pharmacology of Glucagon
- (2017) T. D. Müller et al. PHYSIOLOGICAL REVIEWS
- Glucagon receptor inhibition normalizes blood glucose in severe insulin-resistant mice
- (2017) Haruka Okamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Insulin does not stimulate muscle protein synthesis during increased plasma branched-chain amino acids alone but still decreases whole body proteolysis in humans
- (2016) Sarah Everman et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
- (2016) S. J. Henderson et al. DIABETES OBESITY & METABOLISM
- Obesity and Aging in Humans and Nonhuman Primates: A Mini-Review
- (2016) Kelli L. Vaughan et al. GERONTOLOGY
- Pursuit of a perfect insulin
- (2016) Alexander N. Zaykov et al. NATURE REVIEWS DRUG DISCOVERY
- Reappraisal of GIP Pharmacology for Metabolic Diseases
- (2016) Brian Finan et al. TRENDS IN MOLECULAR MEDICINE
- Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
- (2015) A H Sparre-Ulrich et al. BRITISH JOURNAL OF PHARMACOLOGY
- Minimizing Hypoglycemia in Diabetes
- (2015) DIABETES CARE
- Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects
- (2015) Reinhard H. A. Becker et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys
- (2015) Haruka Okamoto et al. ENDOCRINOLOGY
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass
- (2015) Mark J. Solloway et al. Cell Reports
- Glucose-Dependent Insulinotropic Polypeptide Inhibits Bone Resorption in Humans
- (2014) Anne Nissen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties
- (2013) Vikas K. Bhat et al. BIOCHEMICAL PHARMACOLOGY
- Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
- (2013) M. M. Umapathysivam et al. DIABETES
- Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus
- (2013) D.R. Owens et al. DIABETES & METABOLISM
- Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
- (2013) C. S. Marathe et al. DIABETES CARE
- A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice
- (2013) V. K. Bhat et al. DIABETOLOGIA
- A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice
- (2013) Victor A. Gault et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes
- (2013) Mikkel B. Christensen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- In Vivo Imaging of the Glucagonlike Peptide 1 Receptor in the Pancreas with 68Ga-Labeled DO3A-Exendin-4
- (2013) R. K. Selvaraju et al. JOURNAL OF NUCLEAR MEDICINE
- Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
- (2013) Martin Lorenz et al. REGULATORY PEPTIDES
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
- (2012) Jonathan W. Day et al. BIOPOLYMERS
- Anti-Diabetic Efficacy and Impact on Amino Acid Metabolism of GRA1, a Novel Small-Molecule Glucagon Receptor Antagonist
- (2012) James Mu et al. PLoS One
- Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
- (2011) M. Christensen et al. DIABETES
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Development and Functional Characterization of Insulin-releasing Human Pancreatic Beta Cell Lines Produced by Electrofusion
- (2011) Jane T. McCluskey et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Liraglutide: the therapeutic promise from animal models
- (2010) L. B. Knudsen INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome
- (2010) Andreas Nygaard Madsen et al. JOURNAL OF ENDOCRINOLOGY
- Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
- (2009) Bo Ahrén et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now